Use of enoph1 in the treatment and / or diagnosis of cardiomyopathy or heart failure
By overexpressing Enoph1 in body fluids, cells, or tissues, or by detecting the expression level of Enoph1, the problems of treatment and diagnosis of cardiomyopathy and heart failure have been solved, enabling effective treatment and diagnosis of cardiomyopathy and heart failure.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GENERAL HOSPITAL OF PLA
- Filing Date
- 2026-03-30
- Publication Date
- 2026-06-09
AI Technical Summary
Existing technologies have not effectively utilized Enoph1 in the treatment and diagnosis of cardiomyopathy and heart failure, especially in the treatment and diagnosis of heart failure with reduced ejection fraction and septic cardiomyopathy.
The diagnosis and treatment of cardiomyopathy or heart failure can be achieved by overexpressing Enoph1 or using Enoph1 as a biomarker, by using a vector or Enoph1 protein agonist to overexpress Enoph1 in body fluids, cells or tissues, or by detecting the expression level of Enoph1 gene mRNA or protein.
It has achieved effective treatment of cardiomyopathy and heart failure, improved patient survival rate, reversed myocardial cell damage, restored myocardial cell function, and improved diagnostic efficacy.
Smart Images
Figure CN122168744A_ABST
Abstract
Claims
1. Application of Enoph1 in the preparation of products for the diagnosis, early warning, treatment and / or prevention of cardiomyopathy or heart failure.
2. The application according to claim 1, characterized in that, The products described for the treatment and / or prevention of cardiomyopathy or heart failure include reagents that express or overexpress Enoph1; Preferably, the reagent includes one or more of a vector, a factor that promotes Enoph1 gene transcription, or an Enoph1 protein agonist.
3. The application according to claim 1, characterized in that, The products described for diagnosing and / or providing early warning of cardiomyopathy or heart failure include reagents for detecting the expression level or concentration of Enoph1 gene mRNA or its protein. Preferably, the reagents include one or more of the following: reagents required for reverse transcription, reagents required for PCR, reagents required for BCA method, reagents required for Western blotting method, reagents required for sequencing, or reagents required for mass spectrometry.
4. The application according to any one of claims 1-3, characterized in that, The Enoph1 mentioned includes one or more Enoph1s derived from body fluids, cells, tissues or organs; Preferably, the bodily fluid includes blood; Preferably, the cells, organs, or tissues include those derived from the heart.
5. The application according to any one of claims 1-4, characterized in that, The cardiomyopathy described is septic cardiomyopathy; Preferably, the heart failure is heart failure with reduced ejection fraction.
6. Application of Enoph1 overexpression in the preparation of products for the treatment and / or prevention of cardiomyopathy or heart failure.
7. Application of Enoph1 as a biomarker in the preparation of products for the diagnosis and / or early warning of cardiomyopathy or heart failure.
8. A method for constructing a cardiomyocyte injury model, characterized in that, The construction method described includes knocking out or knocking down Enoph1 in cardiomyocytes; Preferably, the construction method includes using siRNA.
9. The construction method according to claim 8, characterized in that, The target sites of the siRNA include SEQ ID NO: 1-3, preferably SEQ ID NO:
3.
10. The construction method according to claim 9, characterized in that, The positive strand of the siRNA includes SEQ ID NO: 4-6, more preferably SEQ ID NO: 6; and / or, The antisense strand of the siRNA includes SEQ ID NO: 7-9, more preferably SEQ ID NO: 9.